To cool or not to cool: Targeted temperature management to prevent ventricular tachycardia associated with Brugada syndrome.

Autor: Kiefer NJ; Department of Medicine, The Leon H. Charney Division of Cardiology New York University Grossman School of Medicine New York New York USA., Ahuja T; Department of Medicine, The Leon H. Charney Division of Cardiology New York University Grossman School of Medicine New York New York USA.; Department of Pharmacy New York University Langone Health New York New York USA., Caballero A; Department of Pharmacy New York University Langone Health New York New York USA., Pashun RA; Department of Medicine, The Leon H. Charney Division of Cardiology New York University Grossman School of Medicine New York New York USA.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2023 Dec 20; Vol. 11 (12), pp. e8338. Date of Electronic Publication: 2023 Dec 20 (Print Publication: 2023).
DOI: 10.1002/ccr3.8338
Abstrakt: Key Clinical Message: A robust inflammatory and febrile response from acute viral illness such as with SARS-CoV-2 in patients with Brugada syndrome may lead to triggering of ventricular arrhythmias. The use of targeted temperature management (TTM) using cooling devices may mitigate the febrile triggering of ventricular arrhythmias in patients with Brugada syndrome.
Abstract: Brugada syndrome (BrS) is an autosomonal dominant genetic disorder, with a risk of ventricular tachycardia (VT). Triggers of VT in BrS include fevers. Here, we report a case of BrS secondary to SARSs-CoV-2 infection and the use of targeted temperature management (TTM) to decrease fever and prevent VT triggering.
Competing Interests: All authors have nothing to disclose. All of the authors have no conflict of interest. This case report was presented in poster form at the American Heart Association (AHA) Meeting in Chicago, IL from November 5–7, 2022.
(© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje